We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
22
2 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
N/A
Active, not recruiting
2
9.1%
Completed
15
68.2%
Withdrawn
5
22.7%
No approval data available
- The US invasive fungal infections market was valued at nearly USD 390 million in 2025 and is projected to expand significantly through 2036, driven by rising immunocompromised populations and novel antifungal launches. - Approximately 112,000 incident cases of invasive fungal infections occurred in the United States in 2025, with invasive candidiasis and invasive aspergillosis accounting for nearly 50% of the total disease burden. - Nearly 90% of patients eventually develop resistance to first-line antifungal therapy, while around 30% develop resistance to second-line agents, underscoring the urgent need for drugs with novel mechanisms of action. - Promising pipeline candidates including Fosmanogepix, Olorofim, SCY-247, and MAT2203 are advancing through clinical development, with SCY-247 receiving FDA QIDP and Fast Track designations in January 2026.
